Somatostatin analogs in the treatment of castrate-resistant prostate cancer: efficacy and tolerability
Abstract
Castrate-resistant prostate cancer (CRPC) is one of the most complex and currently completely unsolved problems of oncourology. Possible novel treatment of CRPC is administration of Octreotide Long, long-acting somatostatin analogue.
In this paper we have shown an experience of treatment with Octreotide Long 30 mg and dexamethasone in 69 CRPC patients from February 2014 to March 2016.
We have assessed an efficacy and safety of the therapy.
Age of patients ranged from 56 to 89 years, all patients had continued androgen deprivation.
Response to the treatment was assessed clinically by the following factors: change in the level of prostate specific antigen (PSA) in serum, dynamics of indicators of general and biochemical blood tests, the level of pain syndrome and improvement in the patient’s quality of life.
Total response to reduction and stabilization of PSA level was achieved in 70.9 % of patients.
In general, the best results were observed in the group of patients treated with Octreotide Long before first-line chemotherapy with docetaxel.
Tolerability of Octreotide Long in combination with dexamethasone in all cases was good.
No significant side effects – neither hematological, nor clinical were noted. We also did not register any cases of drug discontinuation due to its intolerance.
See also:
- Official Web Site: The Di Bella Method;
- Somatostatin in oncology, the overlooked evidences - In vitro, review and in vivo publications;